Samrat Pharmachem Ltd.
BSE: 530125
₹208.80
₹0.00 (0.00%)As on 10-Jun-2026 13:31IST
Market cap
₹63 Cr
Revenue (TTM)
₹290 Cr
P/E Ratio
--
P/B Ratio
0.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹-3 Cr
-
ROE
10.4 %
-
ROCE
13.6 %
-
Industry P/E
26.06
-
EV/EBITDA
-52.1
-
Debt to Equity
0
-
Book Value
₹220.7
-
EPS
₹-10.7
-
Face value
10
-
Shares outstanding
3,089,700
10 Years Aggregate
CFO
₹9.74 Cr
EBITDA
₹90.16 Cr
Net Profit
₹59.47 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Samrat Pharmachem
| -8.1 | -2.9 | 3.6 | -40.0 | -21.3 | -2.7 | 23.0 |
|
BSE Commodities
| 5.7 | -2.9 | 7.9 | 9.2 | 16.1 | 10.4 | 15.4 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Samrat Pharmachem
| -41.9 | 8.7 | -54.2 | 116.1 | 154.3 | 41.2 | 85.1 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Commodities
| 12.5 | 8.1 | 17.5 | 1.2 | 61.5 | 26.1 | -4.6 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Samrat Pharmachem
|
208.8 | 63.3 | 289.7 | -3.3 | -1.0 | -4.8 | -- | 0.9 |
| 1,816.1 | 9,392.6 | 1,535.9 | 180.0 | 13.9 | 12.1 | 52.2 | 6.1 | |
| 3,314.8 | 14,363.5 | 15,226.8 | 420.1 | 3.4 | 10.7 | 34.2 | 3.6 | |
| 1,506.5 | 19,261.0 | 11,506.0 | 738.8 | 11.0 | 11 | 26.1 | 2.6 | |
| 1,116.4 | 4,814.6 | 2,527.2 | 332.0 | 15.8 | 16.1 | 14.5 | 2.2 | |
| 1,696.6 | 6,030.9 | 5,248.3 | 267.4 | 6.7 | 10.5 | 22.6 | 2.2 | |
| 2,604.0 | 8,439.8 | 15,929.8 | 1,844.4 | 16.6 | 12.4 | 9.1 | 1.1 | |
| 5,164.0 | 7,068.4 | 1,995.6 | 185.3 | 11.7 | 13.8 | 38.2 | 5.1 | |
| 7,105.0 | 35,965.1 | 3,313.9 | 663.6 | 28.1 | 17.7 | 54.2 | 9.0 | |
| 730.8 | 18,686.4 | 14,584.0 | -1,715.0 | 4.1 | -8 | -- | 0.9 |
Shareholding Pattern
View DetailsNews & Analysis
All NewsNo Review & Analysis are available.
About Samrat Pharmachem
Samrat Pharmachem Limited manufactures and sells pharmaceutical chemicals in India. It offers iodine salts and bromines salts, as well as iodine derivatives for industries, such as pharmaceuticals, chemicals, food, fertilizers, salt, etc. The company... also exports its products worldwide. Samrat Pharmachem Limited was founded in 1992 and is based in Mumbai, India. Read more
-
Incorporated
1992
-
Chairman
Lalit Mehta
-
Managing Director
Lalit Mehta
-
Headquarters
Ankleshwar, Gujarat
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
FAQs for Samrat Pharmachem
What is the current share price of Samrat Pharmachem Ltd Today?
The share price of Samrat Pharmachem Ltd is ₹208.80 (BSE) as of 10-Jun-2026 13:31 IST. Samrat Pharmachem Ltd has given a return of -21.29% in the last 3 years.
What is the current PB & PE ratio of Samrat Pharmachem Ltd?
Since, TTM earnings of Samrat Pharmachem Ltd is negative, P/E ratio is not available.
The P/B ratio of Samrat Pharmachem Ltd is 0.93 times as on 10-Jun-2026, a 50 discount to its peers’ median range of 1.87 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
13.59
|
1.35
|
|
2024
|
47.64
|
1.59
|
|
2023
|
6.89
|
1.82
|
|
2022
|
8.72
|
3.20
|
|
2021
|
7.88
|
1.42
|
What is the 52 Week High and Low of Samrat Pharmachem Ltd?
The 52-week high and low of Samrat Pharmachem Ltd are Rs 389.00 and Rs 190.00 as of 10-Jun-2026.
What is the market cap of Samrat Pharmachem Ltd?
Samrat Pharmachem Ltd has a market capitalisation of ₹ 63 Cr as on 10-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Samrat Pharmachem Ltd?
Before investing in Samrat Pharmachem Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.